Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Penpulimab and Anlotinib in Advanced GI and Urinary Tumors
NCT04207463Phase 2Unknown
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Jun 2020
- Primary completion
- Dec 2020
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of penpulimab in cholangiocarcinoma (CCA), colorectal cancer (CRC), gastric cancer (GC), gastroesophageal junction adenocarcinoma, urothelial carcinoma (UC), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Status: unknown.
02
Drugs
penpulimab
03
Conditions
cholangiocarcinoma (CCA)colorectal cancer (CRC)gastric cancer (GC)gastroesophageal junction adenocarcinomaurothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT04207463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04207463.